
  
    
      
        
        Epidemiological_NNP studies_NNS suggest_VBP that_IN statins_NNS ,_, a_DT class_NN of_IN cholesterol-lowering_JJ drugs_NNS ,_, may_MD
        lower_VB the_DT risk_NN for_IN Alzheimer_NNP disease_NN ._. The_DT mechanism_NN for_IN this_DT effect_NN is_VBZ unclear_JJ ._. Alzheimer_NNP
        disease_NN is_VBZ characterized_VBN by_IN accumulation_NN of_IN amyloid_NN deposits_NNS in_IN the_DT brain_NN ._. These_DT deposits_NNS
        are_VBP composed_VBN of_IN amyloid-beta_JJ (_( Aβ_NNP )_) peptide_NN ,_, a_DT protein_NN fragment_NN that_WDT is_VBZ cleaved_JJ off_RP from_IN the_DT
        amyloid_NN precursor_NN protein_NN APP_NNP ._. APP_NNP can_MD be_VB cleaved_JJ in_IN two_CD different_JJ ways_NNS ._. Amyloidogenic_NNP
        (_(“ amyloid_NN generating_NN” )_) cleavage_NN by_IN an_DT enzyme_NN called_VBD beta-secretase_JJ yields_NNS “ sticky_JJ” Aβ_NNP
        peptides_NNS that_IN aggregate_JJ to_TO form_VB deposits_NNS ,_, whereas_IN non-amyloidogenic_JJ cleavage_NN by_IN
        alpha-secretases_JJ generates_VBZ soluble_JJ peptides_NNS that_WDT do_VBP not_RB form_VB deposits_NNS ._. Studies_NNS in_IN animal_NN
        models_NNS and_CC cell_NN culture_NN suggest_VBP that_IN statins_NNS might_MD modulate_VBP APP_NNP processing_NN and_CC shift_VB the_DT
        balance_NN toward_IN “ healthy_JJ” (_( non-amyloidogenic_JJ )_) cleavage_NN ._.
        In_IN their_PRP$ quest_NN to_TO understand_VB how_WRB statins_NNS affect_VBP APP_NNP processing_NN ,_, Sam_NNP Gandy_NNP and_CC colleagues_NNS
        focused_VBN on_IN a_DT molecule_NN called_VBD ROCK_NNP 1_CD ,_, a_DT kinase_NN enzyme_NN that_WDT had_VBD recently_RB been_VBN implicated_VBN in_IN
        APP_NNP processing_NN ._. The_DT theoretical_JJ link_NN between_IN statins_NNS and_CC ROCK_NNP 1_CD goes_VBZ as_IN follows_VBZ :_: statins_NNS
        inhibit_VBP the_DT isoprenoid_NN pathway_NN ,_, isoprenoids_NNS are_VBP regulators_NNS of_IN the_DT enzyme_NN Rho_NNP ,_, and_CC Rho_NNP in_IN
        turn_NN activates_NNS ROCK_NNP 1_CD ._. And_CC while_IN such_JJ potential_JJ connections_NNS could_MD be_VB drawn_VBN for_IN any_DT number_NN of_IN
        molecules_NNS ,_, Gandy_NNP and_CC colleagues_NNS went_VBD on_IN to_TO test_VB whether_IN statins_NNS exert_VB their_PRP$ effect_NN on_IN APP_NNP
        cleavage_NN by_IN interfering_VBG with_IN the_DT isoprenoid_NN /_NN Rho_NNP /_NN ROCK_NNP 1_CD pathway_NN ._.
        Working_NNP in_IN mouse_NN neuroblastoma_NN cells_NNS ,_, they_PRP confirmed_VBD that_IN two_CD different_JJ statins_NNS
        increased_VBD healthy_JJ cleavage_NN of_IN APP_NNP ._. When_WRB they_PRP directly_RB interfered_VBD with_IN the_DT
        isoprenoid_NN /_NN Rho_NNP /_NN ROCK_NNP 1_CD pathway_NN by_IN adding_VBG a_DT drug_NN that_IN inhibits_NNS Rho_NNP activation_NN ,_, they_PRP saw_VBD
        effects_NNS similar_JJ to_TO those_DT of_IN the_DT statins_NNS (_( i_NNP ._. e_SYM ._. ,_, an_DT increase_NN in_IN healthy_JJ cleavage_NN )_) ._. The_DT same_JJ
        effects_NNS were_VBD seen_VBN when_WRB they_PRP transfected_JJ the_DT cells_NNS with_IN a_DT dominant_JJ negative_JJ form_NN of_IN ROCK_NNP 1_CD
        (_( which_WDT inactivates_NNS the_DT normal_JJ ROCK_NNP 1_CD molecules_NNS in_IN the_DT cell_NN )_) ;_: this_DT outcome_NN shows_VBZ that_IN the_DT
        pathway_NN can_MD influence_VB APP_NNP cleavage_NN ._. Most_JJS conclusively_RB ,_, when_WRB they_PRP added_VBD a_DT version_NN of_IN ROCK_NNP 1_CD
        that_WDT was_VBD constitutively_RB (_( always_RB )_) active_JJ ,_, they_PRP reduced_VBD basal_NN levels_NNS and_CC abolished_VBN
        statin-stimulated_JJ levels_NNS of_IN healthy_JJ cleavage_NN ._.
        Taken_VBN together_RB ,_, these_DT results_NNS suggest_VBP that_IN statins_NNS influence_VBP APP_NNP processing_NN ,_, at_IN least_JJS in_IN
        part_NN ,_, by_IN modulating_VBG the_DT isoprenoid_NN pathway_NN and_CC inactivating_VBG the_DT ROCK_NNP 1_CD kinase_NN ._. Future_JJ
        studies_NNS are_VBP necessary_JJ to_TO determine_VB whether_IN this_DT mechanism_NN is_VBZ actually_RB responsible_JJ for_IN the_DT
        apparent_JJ clinical_JJ benefits_NNS of_IN statins_NNS ._. Another_DT question_NN worth_JJ exploring_VBG further_JJ is_VBZ whether_IN
        ROCK_NNP 1_CD might_MD be_VB a_DT suitable_JJ target_NN for_IN therapeutic_JJ interventions_NNS that_WDT aim_NN to_TO decrease_VB
        harmful_JJ ,_, and_CC promote_VB healthy_JJ ,_, cleavage_NN of_IN APP_NNP ._.
      
    
  
